--- title: "16:22 ETZynex Poised for New Future with Resolution of Federal Investigation" description: "Zynex, Inc. has resolved a federal investigation into its business practices, with the U.S. Attorney's Office agreeing not to pursue criminal charges. The company, under new management since August 20" type: "news" locale: "en" url: "https://longbridge.com/en/news/276170205.md" published_at: "2026-02-17T21:23:56.000Z" --- # 16:22 ETZynex Poised for New Future with Resolution of Federal Investigation > Zynex, Inc. has resolved a federal investigation into its business practices, with the U.S. Attorney's Office agreeing not to pursue criminal charges. The company, under new management since August 2025, has implemented extensive changes to ensure compliance and transparency. CEO Steven Dyson emphasized the commitment to rebuild the company and focus on high-quality operations. Zynex expects to emerge from Chapter 11 bankruptcy restructuring in the coming months, following significant operational overhauls and adherence to payor billing guidelines. , /PRNewswire/ -- Zynex, Inc., today announced that it has resolved the federal government's investigation into business practices designed and implemented by the company's former executives. Under the non-prosecution agreement (NPA) signed today, the United States Attorney's Office for the District of Rhode Island (USAO RI) has agreed not to pursue criminal charges against the company and not to require an independent compliance monitor going forward. "The resolution we have achieved today represents the fulfillment of the commitments we made as a new management team when we arrived in August 2025: to break from the past, rebuild the company as compliant-by-design, and create a new future for the company, its customers, and employees," said Steven Dyson, Chief Executive Officer. "Our customers and patients experience a very real benefit from our highly effective products, which has unfortunately been overshadowed by previous business practices. Our entire team has spent six months singularly focused on rebuilding every part of our organization to focus on what matters most: transparency, integrity, and compliance in everything we do so that our high-quality products are supported by high-quality operations." The USAO RI reached its non-prosecution decision in light of the company's "extensive remedial measures," the "internal controls \[the management team\] designed to detect and deter improper billing," and the company's cooperation with the investigation. "We have completely overhauled our order-to-cash processes and implemented a rigorous corporate compliance program," said John Bibb, Chief Legal Officer. "We have aggressively implemented remediation and controls in order to put the past behind us. By adopting well-accepted durable medical equipment (DME) operational and compliance best practices, we have set a strong foundation for the future. With today's announcement, we have swiftly brought to close a series of investigations that began long before new management arrived." Since August 2025, new management has implemented significant changes to the company's business practices, compliance program, and operational controls, including, among other items: - Complete redesign of supplies replenishment practices - requiring explicit and timely confirmation from patients that they need new supplies prior to shipment. - New order intake and fulfilment practices that operationalize medical necessity and payor requirements at the point of intake. - New controls that put a stop to billing practices designed to circumvent payor requirements, including unbundling of supplies. We now require and ensure strict adherence to payor billing guidelines. - New policies ensuring that our marketing activities are on-label and consistent with FDA expectations. Zynex filed for a voluntary financial reorganization under Chapter 11 of the U.S. Bankruptcy Code on December 15, 2025, in the U.S. Bankruptcy Court for the Southern District of Texas, Houston division. With this resolution now in place, the company expects to emerge from Chapter 11 financial restructuring in the next few months. **About Zynex, Inc.** Zynex, founded in 1996, is a pain management device manufacturer and distributor. For additional information, visit: www.zynex.com. **Media Contact: **Britt Logan DiGiulio Email: \[email protected\] SOURCE Zynex, Inc. ### Related Stocks - [ZYXIQ.US - ZYNEX INC](https://longbridge.com/en/quote/ZYXIQ.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | Zynex 公司称，美国证券交易委员会已结束对 Zynex 的调查，并且没有计划采取任何执法行动 | Zynex Inc：ZYNEX INC - 美国证券交易委员会已结束对 ZYNEX 的调查，未计划采取执法行动 - SEC 文件 | [Link](https://longbridge.com/en/news/276385663.md) | | Zymeworks 将举办关于在生命科学服务领域建立商业成熟度的专题讨论会 | Zymewire 将于 2025 年 3 月 4 日举办一场题为 “商业准备：退出硬币的两面” 的小组讨论，届时将邀请专家 Ryan Silvester 和 Elias Sayias。此次活动将重点讨论在当前市场中，生命科学服务提供商是如何 | [Link](https://longbridge.com/en/news/276127348.md) | | Zynex 在第 11 章重组过程中启动了领导层的全面调整 | Zynex Inc.是一家医疗技术公司，目前正在德克萨斯州进行第 11 章重组。该公司已实施全面的领导层改组，并正在加强其合规计划、账单实践和运营控制。Zynex 正与司法部和监管机构密切合作，以应对正在进行的调查，强调其对透明度和诚信的承 | [Link](https://longbridge.com/en/news/273435546.md) | | Zynex 公司提交了第三次修订的第 11 章重组计划，并开始向债权人征求意见 | Zynex, Inc. 已向德克萨斯州美国破产法院提交了第三次修订的第 11 章重组计划，计划于 2026 年 2 月 9 日开始债权人征求意见，投票截止日期为 2026 年 3 月 12 日。该计划包括与计划赞助方的股权交易，并概述了超额 | [Link](https://longbridge.com/en/news/275661130.md) | | 马克斯集团财富管理公司出售了赛默飞世尔科学公司 $TMO 的股票 | Marks Group Wealth Management Inc. 在第三季度减少了对赛默飞世尔（Thermo Fisher Scientific Inc.，NYSE:TMO）44.8% 的持股，目前持有 5,351 股，价值 2,595 | [Link](https://longbridge.com/en/news/276594530.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.